Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -18.75% is 50% above its 5-year average of -37.60%, near the high end of its 5-year range (-69.22%–-1.86%).
30.08% below its 12-month average of -14.41%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1.86%.
EBITDA MARGIN
-18.75%
EBITDA MARGIN AVG TTM
-14.41%
EBITDA MARGIN AVG 3Y
-29.33%
EBITDA MARGIN AVG 5Y
-37.60%
EBITDA MARGIN AVG 10Y
-37.64%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-30.08%
CURRENT VS 3Y AVG
+36.06%
CURRENT VS 5Y AVG
+50.13%
CURRENT VS 10Y AVG
+50.19%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Neuronetics, Inc.
Market Cap
$153.79M
EBITDA Margin
-18.75%
TTM Avg
-14.41%
3Y Avg
-29.33%
5Y Avg
-37.60%
Market Cap
$153.58M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.01M
EBITDA Margin
-48812.58%
TTM Avg
-48812.58%
3Y Avg
-48812.58%
5Y Avg
-48812.58%
Market Cap
$149.36M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
Market Cap
$148.73M
EBITDA Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-2213.91%
5Y Avg
-2345.87%
Market Cap
$148.64M
EBITDA Margin
-316.50%
TTM Avg
-207.34%
3Y Avg
-118.31%
5Y Avg
-106.33%
Market Cap
$159.14M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.79M | -18.75% | -14.41% | -29.33% | -37.60% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | -2.74% | -4.58% | -13.60% | -7.28% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -48812.58% | -48812.58% | -48812.58% | -48812.58% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -239.78% | -210.59% | -2213.91% | -2345.87% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -316.50% | -207.34% | -118.31% | -106.33% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -416.41% | -228.13% | -163.44% | -116.60% |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | -0.19% | -1.66% | -11.02% | -42.72% |
Gross Margin
49.1%
EBITDA Margin
-18.8%
Operating Margin
-14.7%
Net Margin
-19.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1.86% |
| 2026-03-31 | -23.94% |
| 2025-12-31 | -10.24% |
| 2025-09-30 | -17.25% |
| 2025-06-30 | -18.78% |
| 2025-03-31 | -31.60% |
| 2024-12-31 | -49.02% |
| 2024-09-30 | -38.94% |
| 2024-06-30 | -48.34% |
| 2024-03-31 | -36.17% |
| 2023-12-31 | -19.32% |
| 2023-09-30 | -46.81% |
| 2023-06-30 | -38.96% |
| 2023-03-31 | -60.43% |
| 2022-12-31 | -39.14% |
| 2022-09-30 | -42.84% |
| 2022-06-30 | -57.92% |
| 2022-03-31 | -69.22% |
| 2021-12-31 | -44.05% |
| 2021-09-30 | -50.48% |
| 2021-06-30 | -44.31% |
| 2021-03-31 | -53.94% |
| 2020-12-31 | -15.79% |
| 2020-09-30 | -17.81% |
| 2020-06-30 | -68.02% |
| 2020-03-31 | -87.70% |
| 2019-12-31 | -38.25% |
| 2019-09-30 | -37.63% |
| 2019-06-30 | -38.34% |
| 2019-03-31 | -53.83% |
| 2018-12-31 | -34.86% |
| 2018-09-30 | -30.02% |
| 2018-06-30 | -37.07% |
| 2018-03-31 | -43.99% |
| 2017-12-31 | -33.80% |
| 2017-09-30 | -25.37% |
| 2017-06-30 | -23.62% |
| 2017-03-31 | -50.80% |
